ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2346

Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis

Pauline KRUG1, Anthony Lichaa1 and Adrien Nzeusseu Toukap2, 1Cliniques universitaires St-Luc, Brussel, Belgium, 2Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium

Meeting: ACR Convergence 2024

Keywords: Ankylosing spondylitis (AS), Disease-Modifying Antirheumatic Drugs (Dmards), Nonsteroidal antiinflammatory drugs (NSAIDs), spondyloarthritis, Therapy, alternative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Treatment Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive chronic inflammatory disease. In its early stages, symptoms appear without radiographic evidence. Later, structural lesions are observed on radiographs, among which ankylosis. However, the progression to ankylosis remains highly variable. Thus, extensive research has identified different biomarkers and predictors. However, how treatment modalities affect the associations between ankylosis and risk factors is still unclear. This study aims to identify clinical factors associated with ankylosis in axSpA through a subgroup analysis based on two different treatment modalities: non-steroidal anti-inflammatory drugs (NSAIDs) or biologic disease-modifying anti-rheumatic drug (bDMARD).

Methods: We performed a in an academic hospital a nested case-control study utilizing data from a prospective cohort of axSpA patients. Diagnosis was based on the ASAS criteria for radiographic axial spondyloarthritis (r-axSpA) and the modified New York criteria for ankylosing spondylitis. Cases of ankylosis were identified through imaging protocols, supervised by a senior radiologist while controls were selected from the same cohort, showing no ankylosis at the last follow-up. Controls were matched with cases by age, sex, and treatment category (NSAIDs or biological treatments including TNF-alpha blockers and IL17 blockers) in a 1:1 ratio. See Figure .

Results: 141 patients (16%) had ankylosis, among which 76 were treated with NSAIDs and 65 with bDMARDs. The disease duration and smoking were risk factors for ankylosis, independent of treatment. Active smoking was however associated with a higher odds ratio for patients treated with NSAIDs (OR = 6.10, p < 0.0001) compared to those treated with bDMARDs (OR = 2.72, p = 0.02). In patients treated with NSAIDs, a history of uveitis (OR = 3.3, p = 0.02) and chronic elevation of C-reactive protein (CRP) (OR = 1.03, p < 0.0001) were associated with ankylosis, whereas in patients on bDMARDs, elevated CRP (OR = 1.03, p = 0.05) but not past history of uveitis was associated with ankylosis. See Table.

Conclusion: In this nested case-control study, results suggest that the risk factors of progression to ankylosis in axSpA are different between patients on NSAIDs and those on bDMARDs. We need further studies to increase our understanding about these findings and better address ankylosis risk factors.

Supporting image 1

Figure : Study inclusion flow-chart

Supporting image 2

Table: Multivariate analysis of predictors of ankylosis stratified by treatment


Disclosures: P. KRUG: None; A. Lichaa: None; A. Nzeusseu Toukap: AbbVie/Abbott, 6, Amgen, 5, Eli Lilly, 1, Janssen, 1, 5, 6, Novartis, 6, UCB, 1, 6.

To cite this abstract in AMA style:

KRUG P, Lichaa A, Nzeusseu Toukap A. Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/treatment-effect-on-predictors-of-ankylosis-in-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-effect-on-predictors-of-ankylosis-in-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology